Patients with conditions that could confound MCV (hydroxyurea exposure, megaloblastic anemia, hypothyroidism, chronic liver disease, alcoholism) were excluded. MCV elevation during imatinib therapy is associated with deeper molecular response and reduced need for treatment modification. MCV dynamics may serve as an inexpensive pharmacodynamic marker to support risk assessment and guide monitoring in chronic-phase CML.

The patient was managed with cytoreductive therapy; initially, hydroxycarbamide and anagrelide, later transitioned to ruxolitinib, alongside lifelong anticoagulation. At six-month follow-up, he demonstrated improved LFTs, stable blood counts, and no recurrent thrombotic events, with ongoing surveillance for variceal bleeding. This case underscores the importance of considering BCS in patients with ET and hepatic abnormalities, screening for AvWS to balance thrombotic/bleeding risks, and utilizing a multidisciplinary team (MDT) approach for optimal management.

P1, N=85, Active, not recruiting, Boundless Bio | Recruiting --> Active, not recruiting | N=127 --> 85

This case suggests that JAK2 gene testing should be conducted for unexplained thrombocytosis; occult infection must be investigated when myeloproliferative neoplasm patients develop leukocytosis; maintaining therapeutic balance is crucial in the dual crisis of thrombosis and sepsis.

She was initially treated with low-dose acetylsalicylic acid, with partial improvement, but microvascular symptoms persisted, and platelet counts remained >1,000 × 10⁹/L. Hydroxyurea was initiated, leading to progressive platelet reduction and marked clinical benefit...Cytoreductive therapy may be indicated in cases with extreme thrombocytosis or refractory symptoms, and long-term follow-up is crucial to monitor disease evolution and treatment outcomes. This case highlights the need for multicenter studies and international registries to have pediatric-specific evidence that can better inform diagnostic and therapeutic strategies.

P1, N=19, Terminated, Boundless Bio | Completed --> Terminated; Strategic decision made following an assessment of preliminary PK data from the Part 1 portion of the trial showing a lack of dose proportional exposure and the increasing complexity and associated development costs in this landscape.

Herein, we report two such novel 3D coordination polymers of zinc-inosine-5'-monophosphate (Zn-IMP) and bpe/azpy (as linkers) which were engineered as metal-organic frameworks that can be used as drug carriers for hydroxyurea (HU)...Across acidic pH, for CP-1 the ligand RMSD increases markedly and U becomes slightly less negative, which indicated partial loss of contacts, thus releasing drugs in a tumor-like environment more easily. These result showed that CP-1 offers stronger binding, higher structural stability and a more pronounced pH-responsive release profile than CP-2, making CP-1 more promising candidate for targeted HU drug delivery, while CP-2 may serve as a weaker-binding, faster-release complement.

Severe anemia and neutropenia induced by R788 in the sickle mouse model suggests that concomitant use of Syk inhibitors with hydroxyurea in patients with SCD should be approached cautiously. Further research is required to clarify the benefits and risks of selective Syk inhibition in SCD and other hemolytic conditions exhibiting stress hematopoiesis.

Treatment comprised phlebotomy, low-dose aspirin, hydroxyurea, and statin therapy. Ischemic stroke can be the initial presentation of JAK2-positive erythrocytosis consistent with polycythemia vera. Careful framing of diagnostic certainty, early hematocrit control, antithrombotic therapy, and risk-factor optimization are key, especially where resources are limited.

PARP1 and MnSOD were upregulated, but not OGG1, which indicates GRE's selective action. Our findings confirm its genoprotective effects against hydroxyurea-induced DNA damage in peripheral blood mononuclear cells, indicate a complex mechanism of action, and call for further research of this promising compound against secondary genotoxic effects of hydroxyurea.

The patient fully recovered and completed induction without complications. This case highlights the importance of recognizing CS as a rare presenting feature of leukemia, and supports hydroxyurea bridging as a viable strategy when immediate chemotherapy is contraindicated to support surgical recovery.

The patient was managed with drugs such as hydroxyurea, antiplatelet drugs, and phlebotomy. The most notable feature of this intriguing case is PV manifesting as idiopathic intracranial hypertension and vision loss despite normal patent sinuses, which is explainable by hypercoagulability causing sluggish flow in venous sinuses and raised pressure over the optic nerves, resulting in papilledema and vision loss.